Podotimod in pediatric recurrent respiratory tract infections: a cost-utility analysis

INTRODUCTION: Despite the growing evidence on efficacy, few economic evaluations have evaluated the cost-utility of Pidotimod (PDT) supplementation to decrease the probability of recurrent respiratory tract infections in children. This study aimed to determine the cost-utility of PDT to reduce the i...

Descripción completa

Detalles Bibliográficos
Autores principales: Buendía, Jefferson Antonio, Guerrero Patiño, Diana, Lindarte, Erika Fernanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219210/
https://www.ncbi.nlm.nih.gov/pubmed/35739542
http://dx.doi.org/10.1186/s12890-022-02029-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219210/
https://www.ncbi.nlm.nih.gov/pubmed/35739542
http://dx.doi.org/10.1186/s12890-022-02029-4

Ejemplares similares